TI
ALXN

Turner Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Turner Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,180
Closed -$144K – 242
2017
Q2 		$144K Sell
1,180
-180
-13% -$20.9K 0.09% 219
2017
Q1 		$165K Sell
1,360
-9,455
-87% -$1.22M 0.11% 195
2016
Q4 		$1.32M Sell
10,815
-19,655
-65% -$2.41M 0.53% 75
2016
Q3 		$3.73M Buy
30,470
+19,590
+180% +$2.52M 1.24% 19
2016
Q2 		$1.27M Buy
+10,880
New +$1.54M 0.4% 77
2015
Q2 		– Sell
-31,584
Closed -$5.47M – 418
2015
Q1 		$5.47M Sell
31,584
-15,984
-34% -$2.89M 0.98% 20
2014
Q4 		$8.8M Sell
47,568
-81,323
-63% -$15.1M 1.05% 8
2014
Q3 		$21.4M Buy
128,891
+75,783
+143% +$12.4M 1.28% 6
2014
Q2 		$8.3M Sell
53,108
-29,882
-36% -$4.72M 0.37% 72
2014
Q1 		$12.6M Sell
82,990
-88,610
-52% -$14.1M 0.34% 86
2013
Q4 		$22.8M Buy
171,600
+9,077
+6% +$1.09M 0.41% 77
2013
Q3 		$18.9M Sell
162,523
-65,607
-29% -$7.2M 0.31% 103
2013
Q2 		$21M Buy
+228,130
New +$22M 0.28% 135

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Turner Investments's ALXN Position: Q3 2017 in Review

Turner Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 1,180 shares — an estimated $144K sold.

Turner Investments first reported a position in ALXN in Q2 2013 and held it in 13 quarters. The position peaked at $22.8M in Q4 2013. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Turner Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Turner Investments sold 1,180 Alexion Pharmaceuticals shares in Q3 2017, an estimated $144K.
  • Turner Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Turner Investments's Alexion Pharmaceuticals position peaked at $22.8M in Q4 2013.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Turner Investments's 13F filing for Q3 2017, filed 8 Nov 2017.